
Faculty & Staff Research and Creative Activity

3-25-2021

Impacts of DigestaWell NRG Supplementation on Post Exercise Muscle Soreness in Unconditioned Horses, a Pilot Study

Jessica K. Suagee-Bedore
The Ohio State University

Yeting Shen
Murray State University

Shea Porr
Murray State University, cporr@murraystate.edu

Ivan D. Girard
Probiotech International

Karen Bennett-Winbrush
The Ohio State University

Follow this and additional works at: <https://digitalcommons.murraystate.edu/faculty>



Part of the [Animal Sciences Commons](#)



This work is licensed under a [Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License](#).

Recommended Citation

Suagee-Bedore, J. K., Shen, Y., Porr, S., Girard, I. D., Bennett-Wimbush, K., & Wagner, A. L. (2021). Impacts of DigestaWell NRG Supplementation on Post Exercise Muscle Soreness in Unconditioned Horses, a Pilot Study. *Journal of Equine Veterinary Science*, 101, 103455. doi.org/10.1016/j.jevs.2021.103455

This Journal Article is brought to you for free and open access by Murray State's Digital Commons. It has been accepted for inclusion in Faculty & Staff Research and Creative Activity by an authorized administrator of Murray State's Digital Commons. For more information, please contact msu.digitalcommons@murraystate.edu.

Authors

Jessica K. Suagee-Bedore, Yeting Shen, Shea Porr, Ivan D. Girard, Karen Bennett-Winbrush, and Ashley L. Wagner

1 **Impacts of DigestaWell NRG® supplementation on post exercise muscle soreness in**
2 **unconditioned horses, a pilot study**

3 J. K. Suagee-Bedore¹, Y. Shen², S. Porr², I. D. Girard³, K. Bennett-Wimbush¹, A. L. Wagner³

4 ¹The Ohio State University, Wooster, OH

5 ²Murray State University, Murray, KY

6 ³Probiotech International, St-Hyacinthe, Quebec, Canada

7

8

9 Funding: This project was funded by a donation from Probiotech International.

10 **Abstract**

11 Exercising horses are commonly plagued by muscle fatigue and soreness, which can
12 result in reduced performance ability. In the present study, ten unconditioned horses were fed
13 200g per day DigestaWell® NRG, a commercial dietary supplement containing *Yucca*
14 *schidigera* and *Trigonella foenum-graecum*, two herbs shown in other species to reduce post-
15 exercise muscle pain and soreness. A control, unsupplemented group contained ten horses of
16 similar age, breed, and gender. Horses completed a 50 min, ridden standardized exercise test of
17 moderate intensity immediately prior to (Period1) and after 28 d of supplementation (Period2).
18 Muscle soreness and tightness were evaluated 24 h prior to and after each exercise test and used
19 to determine the percent increase in post-exercise muscle soreness and tightness. Blood samples
20 were collected before, and at 10 and 30 min, and 1, 4, and 24 h post exercise. Plasma was
21 analyzed for glucose, lactate, non-esterified fatty acid (NEFA), tumor necrosis factor- α (TNF α),
22 and interleukin-1 β (IL-1 β) concentrations. Data were analyzed by repeated measures ANOVA
23 using SAS Enterprise Guide v. 7.1. No changes in plasma parameters were indicated between
24 periods for unsupplemented horses ($P > 0.1$) during Period2, excepting glucose, which was
25 greater during Period2 ($P = 0.018$). Supplemented horses had lesser concentrations of TNF α ($P =$
26 0.016) and lactate ($P = 0.058$) during Period2 than during Period1. During Period2,
27 supplemented horses experienced a smaller percent increase in post exercise muscle soreness (P
28 $= 0.031$). DigestaWell® NRG supplementation may benefit unconditioned horses undergoing
29 moderate intensity exercise through reducing lactate production and inflammation.

30 **Keywords:** fenugreek; lactate; muscle soreness; NEFA; yucca

31 **Introduction**

32 Muscular soreness is a result of ultrastructural muscle injury. As shown in humans, post
33 exercise muscle soreness is due in part to a cascade of responses initiated by damaged Z bands
34 and loss of contractile proteins, which results in neutrophil infiltration into muscle and
35 production of interleukin 1- β (IL-1 β) and tumor necrosis factor- α (TNF α) by immune cells [1-4].
36 These cytokines act to increase expression of pain-sensing pathways in muscle cells through
37 prostaglandin production [5-7]. Horses that are in pain frequently exhibit behavioral problems
38 such as bucking and rearing [8, 9] that put them at risk for welfare concerns if their owners do
39 not recognize the underlying health problem. This indicates that there could be a high frequency
40 of welfare concerns in the non-racing population, because muscular pain and lameness are
41 common concerns of horse owners, with owners citing concurrent poor performance or
42 misbehaviors in horses diagnosed with lameness [10, 11]. Post-exercise muscle soreness and
43 increased serum creatinine kinase activity were induced in horses carrying 30% of their
44 bodyweight during a moderate-intensity 45 min exercise protocol designed to mimic a riding
45 lesson [12], while lameness was induced in previously-sound horses undertaking a 30 min
46 dressage test, when carrying more than 17.3% of bodyweight [13]. These studies indicate a
47 potential for muscle damage and poor welfare of horses carrying >17% of bodyweight during
48 moderate intensity exercise, a level of exercise that more horses participate in than racing [14].

49 Use of herbal supplements, which can be used to moderate the physiological responses to
50 a painful stimulus in mice [15], is increasing in human populations and they are more commonly
51 given to horses as well [16-19]. One such plant, yucca (*Yucca schidigera*) exhibits anti-
52 inflammatory activity through one of its active components, resveratrol [20], which reduces
53 eicosanoid synthesis through inhibiting COX enzyme activity [21]. Fenugreek (*Trigonella*

54 *foenum-graecum*) also contains anti-inflammatory compounds that reduce muscle pain through
55 reducing cell membrane peroxidation [22] and has pain relieving properties similar to over-the-
56 counter medications, as tested in mice [15].

57 Fenugreek has metabolism-altering actions which could reduce muscle fatigue through
58 enhancing nutrient availability during exercise. Fenugreek-supplemented mice experienced
59 lower blood lactic acid concentrations following exhaustive exercise than unsupplemented mice
60 [23]. Fenugreek supplementation also lengthened time to exhaustion and increased post-exercise
61 glycogen resynthesis rates in both humans and mice [24, 25]. For these reasons, we modified a
62 ridden exercise protocol that was previously shown to induce muscle soreness [12], in order to
63 evaluate DigestaWell® NRG, a dietary supplement containing yucca and fenugreek. The
64 hypothesis was that DigestaWell® NRG would benefit unconditioned horses undergoing a bout
65 of moderate-intensity exercise by reducing post-exercise muscle soreness. Secondly, we
66 hypothesized that horses receiving the supplement would have reduced concentrations of both
67 circulating inflammatory cytokines and lactic acid following exercise.

68

69 **Materials and Methods**

70 *Horse Management*

71 The Institutional Animal Care and Use Committee of Murray State University approved the use
72 of horses for this study. Twenty mature, healthy horses from Murray State University's equine
73 program were selected for use in this study. Horses were blocked into three groups by age (11 to
74 15 years, n=11; 16 to 20 years, n=5; >20 years, n=4), and then assigned either to treatment
75 (NRG) or control (CON; Table 1). Horses assigned to the CON group included 9 Quarter Horses
76 and 1 Thoroughbred; while the NRG group included 6 Quarter Horses, 2 Thoroughbreds, and 2

77 warmbloods. Eight geldings and 2 mares were assigned to the CON group; while 9 geldings and
78 1 mare were assigned to the NRG group. All mares were non-pregnant. Although breed and
79 gender numbers differed, the investigators considered age as the primary blocking factor. Body
80 condition score (BCS) was determined on a scale of 1-9 prior to the first SET at the same time
81 bodyweight was measured [26]. Horses were between a (BCS) of 5 to 6.5 (Table 2). Sixteen of
82 these horses were housed on well managed Coastal-Bermudagrass pasture, while 4 of the
83 geldings (CON n=1; NRG n=3) were housed in stalls because they developed anxious behaviors
84 when turned out for long periods of time. Stalled horses were unequally divided amongst
85 treatments because age was considered the primary blocking factor. Stalled horses received
86 several hours of daily turnout onto adjacent pastures and were offered *ad libitum* Coastal
87 Bermudagrass hay (Table 3) when stalled. The hay was from the same batch throughout the
88 study. Horses received concentrate in amounts necessary to maintain condition, with pastured
89 horses receiving a maintenance concentrate (11-Six Pelleted Horse Feed, Southern States
90 Cooperative, Richmond, VA; Table 2) at 0.2 kg per day, with a predominant purpose of carrying
91 the supplement. Stalled horses receiving a higher calorie concentrate, due to individual
92 tendencies to lose condition (Triple 10 Texturized Feed, Southern States Cooperative) at 0.5 to
93 0.7% of bodyweight per day (Table 3). Horses were fed their total feed divided into two equal
94 feedings, twice daily. Amounts of nutrients consumed were calculated as the sum of concentrate,
95 hay (stalled horses only), and pasture, with hay and pasture intake estimated based on equations
96 [27, 28]. Nutrient intake by treatment and housing are presented in Table 4. First daily feedings
97 took place between 0730 and 0900, as horses were individually fed in order to observe feed and
98 supplement consumption. Second daily feedings occurred at 1500. All horses had *ad libitum*
99 access to water and trace mineralized salt blocks (Southern States Cooperative). Feeds were

100 analyzed for nutritional content by Equi-Analytical (Ithaca, NY), while vitamin C and E analysis
101 was conducted by NP Analytical Laboratories (St. Louis, MO).

102 *Treatments*

103 Horses assigned to the treatment diet received 200 grams of a nutritional supplement,
104 DigestaWell NRG® (Probiotech International, Saint-Hyacinthe, Quebec, Canada) once a day,
105 during the morning offering of feed, for a total of 4 weeks. The *Yucca schidigera* and *Trigonella*
106 *foenum-graecum* used to produce the DigestaWell NRG® product were in the form of powdered
107 extracts that were blended into a dry carrier of ground alfalfa, wheat middlings, and grape
108 pomace. Liquid flavors (vanillin and diacetyl) were dried over silica to convert them to dried
109 powders. Ceylon cinnamon was included as a flavor and was included as a dried powder. Yeast
110 culture was included as well as the preservative, calcium propionate. The product is delivered to
111 the horse in a powdered form. Pastured horses were brought one at a time into a small paddock
112 where they had access to the supplement for 10-15 min. Horses remained in the paddock until
113 consumption was complete or the horse showed no interest in the feed for at least 5 min despite
114 encouragement to eat. No horses finished the supplement on d 1. By d 3, all pastured horses
115 consumed the entire supplement and their feed ration within 15 min. Originally, three stall horses
116 were assigned to the NRG treatment. Stalled horses had access to the supplement for 60 min,
117 because one stalled horse regularly refused at least 100 g of supplement, and never consumed all
118 200 g at any point during the study. Due to lack of compliance, this horse's data was dropped
119 from the statistical analysis. The other two stalled horses assigned to NRG, regularly consumed
120 their entire supplement and feed. Therefore, the CON treatment contained one stalled horse and
121 the NRG treatment contained two.

122 *Standardized Exercise Test*

123 A ridden standardized exercise test (SET, Table 5) similar to that conducted by Powell et al.
124 [12], was conducted prior to the start (Period1) and following the conclusion of the study
125 (Period2). For this SET, horses exercised for a total of 50 min, consisting of 2.5 min of brisk
126 walking, 15 min of trotting, 5 min of canter, 2.5 min of trotting, reversing direction, 2.5 min of
127 brisk walking, 15 min of trotting, 5 min of canter, and 2.5 min of trotting. Horses were to trot at
128 approximately 3 m/s and canter at 5 m/s. Horses were randomly allocated to one of three groups,
129 with each group assigned to a consecutive day for performing the SET. Seven horses were
130 assigned to d 1 (NRG n=4; CON n=3), 6 horses to d 2 (NRG n=2; CON n=4), and 7 horses to d 3
131 (NRG n=4; CON n=3). Prior to the start of this study (January – May), horses participated in
132 riding classes and equestrian team practices, however they had not received any forced exercise
133 for six weeks before the start of the study. With the exception of the standardized exercise test,
134 horses did not receive forced exercise during this trial.

135 The SETs were conducted in a 30 x 60-meter indoor arena with horses carrying 20% of
136 their body weight. Prior to the start of the SET, each horse was weighed on a livestock scale
137 while wearing only a halter. Following this, the rider was weighed along with tack, which
138 included a roping-style western saddle, cinch, saddle pad, breast collar, and bridle. Additional
139 weights were added to the scale in order to reach 20% of horse bodyweight. Weights consisted of
140 custom-made nylon bags containing lead pellets at weights of 1, 5, and 10 pounds. Bags had
141 grommets sewn in which allowed attachment to the saddle through use of carabineer clips.
142 Placement of weights were equally distributed on the saddle from side to side and front to back
143 in order to prevent tipping and pulling on the saddle. Horses were walked around to desensitize
144 them to the feeling of these bags, yet no negative reactions were indicated. During the SET,
145 cones were placed every 15 m, with horses needing to trot the distance in 5 s and canter the

146 distance in 3 s. An assistant on the ground kept time and advised the rider to increase or decrease
147 speed to meet requirements. Riders and assistants had participated in previous exercise research
148 trials and were familiar with the protocol. During the SET's, horses wore heart rate monitors
149 (Equine H7, Polar USA, Bethpage, NY) that transmitted heart rate data to a wrist watch worn by
150 the rider. Heart rate data from watches were recorded after horses were tacked up, after standing
151 still for several minutes, at the end of each gait during the SET, and at 10 and 30 min post
152 exercise (Figure 1). Riders dismounted immediately after the completion of the exercise test and
153 horses were untacked after post-exercise vitals were obtained. Six advanced level riders from the
154 MSU equitation program participated in this project and were blinded to treatment as they only
155 participated in the riding portion. Riders were rotated and allowed breaks between exercise
156 sessions. Riders were matched with horses in order to effectively meet the 20% of bodyweight
157 goal.

158 *Massage testing*

159 A licensed equine massage therapist, blinded to treatments, conducted a muscle soreness and
160 tension exam on each horse 24 h before and 24 h after each SET (Figure 1) [12]. The system
161 used a Likert-type scale to grade the severity of muscle soreness and tightness in horses and
162 ranged from 0 (no soreness/tightness) to 2.5 (extremely tight or sore). The scoring system
163 included 10 muscles: the trapezius, deltoid, rhomboideus, latissimus dorsi, longissimus, triceps,
164 biceps, gluteals, hamstring group, and tensor fascia lata, on the left and right sides of the horse.
165 The massage therapist pressed a blunt plastic evaluation tool into the muscle and moved it
166 caudally (trapezius, rhomboideus, latissimus dorsi, longissimus) or distally (triceps, deltoid,
167 biceps, gluteals, hamstring, tensor fascia lata) along the muscle using consistent pressure. For
168 each muscle and on each side of the horse, a soreness score and a tightness score were separately

169 recorded, therefore, each muscle on each side ranged from 0 (no soreness or tightness) to 2.5
170 (extremely sore or extremely tight). Muscle soreness and tightness scores from both sides of the
171 horse and all muscles were summed for each horse during each evaluation, yielding a value that
172 ranged from 0 (no soreness or tightness) to 100 (extremely sore and tight in each muscle on both
173 sides of the horse). These values were used to calculate percent change within each period,
174 which was calculated as $(\text{Period2} - \text{Period1})/\text{Period2}$, yielding two numbers per horse (pre-
175 supplement[Period1] and post-supplement[Period2]).

176 *Blood sampling and sample analysis*

177 Blood samples were obtained via jugular venipuncture prior to the start of the SET (time 0) and
178 at 10 and 30 min and 1, 4, and 24 h post exercise (Figure 1). Samples were collected into
179 evacuated heparin and EDTA coated tubes (Vacutainer, Becton, Dickinson and Company,
180 Franklin Lakes, NJ) and then placed on ice in a cooler until centrifugation (<2 h). Plasma was
181 harvested and stored at -20°C until later analysis. All samples were analyzed in duplicate.

182 Plasma glucose and L-lactate concentrations were determined using commercially
183 available enzymatic assay kits (2300 Stat Plus, YSI Inc., Yellow Springs, OH) designed for the
184 YSI 2700 Select system (YSI Inc., Yellow Springs, OH). Plasma IL-1 β and TNF α were analyzed
185 using enzyme linked immunosorbent assays with methods previously published for use in the
186 horse [29, 30]. Briefly, plasma samples were analyzed for TNF α using Nunc-Immuno 96
187 MicroWell flat bottom plates (Nalge Nunc International, Rochester, NY, USA) following a 1:4
188 dilution. The blocking buffer used for all assays consisted of 4% ELISA-grade BSA
189 (Calbiochem, La Jolla, CA, USA), and 5% sucrose (Fisher Scientific, Fair Lawn, NJ, USA), in
190 BuPH phosphate-buffered saline (ThermoFisher Scientific, Waltham, MA). Plates were washed
191 in a solution of 0.05% Tween 20 (Fisher Scientific) in phosphate-buffered saline. The

192 manufacturer's instructions were followed, except an additional wash step was included after
193 blocking. For IL-1 β , plates were coated overnight with 3 μ g/mL of capture antibody (prepared in
194 DPBS), blocked for one hour with reagent diluent (4% BSA in DPBS), and then incubated with
195 samples (diluted 1:2 in DPBS) for one hour. Following sample incubation, plates were incubated
196 with detection antibody prepared at 3 μ g/mL in DPBS and allowed to react with streptavidin-
197 HRP (Kingfisher Biotech Inc., St. Paul, MN) for 30 minutes prior to incubation with substrate
198 solution (Kingfisher Biotech) for 30 minutes. Reactions were stopped with the addition of stop
199 buffer (Kingfisher Biotech). Rinsing protocols were the same as for the TNF α ELISA. ELISAs
200 were read at 450 nm. Non-esterified fatty acid concentrations were analyzed using a
201 commercially available spectrophotometric assay (Zenbio, Research Triangle Park, NC). Intra
202 and inter-assay CV's were 3.9 and 11.5% for TNF α , 7.6 and 13.2% for IL-1 β , and 7.2 and 5.9%
203 for NEFA. Intra-assay CV's for glucose and lactate were 1.3 and 2.5%, respectively.

204 *Statistics*

205 All statistical analyses were performed using the MIXED procedure of SAS (v. 9.4, Cary, NC).
206 For all analyses, normality and homogeneity of variance of residuals was determined through use
207 of influence statistics and visual analysis of residual box and whisker plots. Outliers were
208 determined through evaluation of the Internally Studentized Residual, with values >2.7 or <-2.7
209 being scrutinized. For all repeated measures analyses, the covariance structure yielding the
210 lowest AICC index was selected for each analysis. Simple effect differences for a main effect of
211 time were detected using a Dunnett test, which compares each time point to time 0, reducing the
212 number of multiple comparisons. For all analyses, significance is considered at $P < 0.05$ and a
213 tendency at $P < 0.09$.

214 Data for bodyweight and body condition scores were analyzed using repeated measures
215 ANOVA for the main effects and interaction of period and treatment (trt), where the repeated
216 effect was period and horse was a random effect. The statistical model was $\gamma = \mu + \text{horse} + \text{period} +$
217 $\text{trt} + \text{period} * \text{trt} + \epsilon$. Data are presented as the mean \pm SEM. Mean nutrient intakes were analyzed
218 for the effect of treatment and data are presented as the mean \pm SEM.

219 Heart rate and plasma glucose, lactate, NEFA, IL-1 β , and TNF α data were analyzed using
220 repeated measures ANOVA for the effects and interactions of time and period within treatment.
221 The statistical model was $\gamma = \mu + \text{time}(\text{trt}) + \text{period}(\text{trt}) + \text{time} * \text{period}(\text{trt}) + \epsilon$. Muscle soreness
222 data were analyzed for the main effect of period within treatment, with a statistical model of $\gamma =$
223 $\mu + \text{period}(\text{trt}) + \epsilon$. Day of SET (horses were assigned to one of three consecutive testing days
224 during each period) included as a random effect. For all analyses except IL-1 β , a covariate (time
225 0 value) was found to be significant ($P < 0.001$), and therefore included in the model. All plasma
226 variables required transformation to achieve normality and homogeneity of variance. Therefore,
227 plasma variable means are presented as geometric means bounded by the 95% confidence
228 interval. Heart rate and muscle soreness data are presented as means \pm SEM.

229

230 **Results**

231 *Bodyweight, body condition scores, and nutrient consumption*

232 Neither bodyweight nor body condition score were affected by period, treatment or the period by
233 treatment interaction ($P > 0.1$; Table 2). Nutrient intakes were not different between treatments
234 ($P > 0.1$; Table 4).

235 *Heart Rate*

236 Neither the time by period interaction nor period affected heart rates for NRG or CON
237 horses ($P > 0.6$; Table 5). However, heart rates were affected by time for both treatments ($P <$
238 0.001), whereby heart rates were elevated above baseline at all time points except post 30
239 minutes ($P < 0.05$).

240 *Plasma Metabolites*

241 Neither the time by period interaction nor period affected plasma glucose concentrations
242 for NRG or CON horses ($P > 0.1$; Figure 2A, B). Period affected plasma glucose concentrations
243 for CON horses only ($P = 0.018$), whereby plasma glucose was higher ($P = 0.018$) during
244 Period2 [5.1 [5.0, 5.2] mmol/L) than Period1 [4.8 [4.7, 4.9] mmol/L). Period did not affect
245 plasma glucose concentrations for NRG ($P > 0.5$).

246 There was no effect of the time by period interaction on plasma lactate concentrations for
247 NRG or CON horses ($P > 0.4$; Figure 2C, D). For CON horses, there was an effect of time ($P <$
248 0.001) but not period ($P > 0.3$), whereby lactate concentrations, when averaged across periods,
249 were higher at 10 min (1.27 [1.16, 1.39] mmol/L; $P < 0.001$) and 30 min (0.99 [0.90, 1.08]
250 mmol/L; $P < 0.001$) post exercise than baseline concentrations (0.57 [0.52, 0.63] mmol/L). For
251 NRG horses, there was an effect of time ($P = 0.021$). Similar to CON horses, lactate
252 concentrations, when averaged across periods, were elevated above baseline (0.43 [0.39, 0.47]
253 mmol/L) at 10 min (0.96 [0.88, 1.06] mmol/L; $P < 0.001$), 30 min (0.71 [0.88, 1.06] mmol/L; P
254 < 0.001), and also 1 h (0.59 [0.54, 0.65] mmol/L; $P = 0.040$) post exercise. Average lactate
255 concentrations tended to be higher during Period1 (0.65 [0.61, 0.69] mmol/L) than Period2 (0.58
256 [0.54, 0.61]; $P = 0.058$).

257 There was no effect of the time by period interaction on plasma NEFA concentrations for
258 NRG or CON horses ($P > 0.1$; Figure 2E, F). For CON horses, there was an effect of time ($P <$

259 0.001) but not period ($P > 0.4$), whereby NEFA concentrations, when averaged across periods,
260 were greater at 10 min (551 [451, 674] μM ; $P < 0.001$), 30 min (310, [253, 381] μM ; $P < 0.001$),
261 and 1 h (191 [156, 233] μM ; $P < 0.01$) than baseline (98 [81, 120] μM). For NRG horses, there
262 was a main effect of time ($P < 0.001$) but not period ($P > 0.7$), whereby NEFA concentrations
263 were greater at 10 min (702 [599, 824] μM ; $P < 0.001$) and 30 min (378, [322, 443] μM ; $P <$
264 0.001) than baseline (164 [140, 193] μM).

265 *Plasma Inflammatory Cytokines*

266 There was no effect of the interaction of time and period for plasma TNF α concentrations
267 for NRG or CON horses ($P > 0.5$; Figure 3 A, B). For CON horses, there was no effect of time or
268 period ($P > 0.4$). For NRG horses, there was no effect of time ($P > 0.7$), but concentrations were
269 lower during Period2 (170, [167, 173] pg/mL) than Period1 (182, [178, 185] pg/mL; $P = 0.012$).
270 There were no effects or interactions of time and period for CON or NRG horses for plasma IL1-
271 β concentrations ($P > 0.2$; Data Not Shown).

272 *Muscle Soreness*

273 The percent increase in muscle soreness and tightness was lower during Period2 ($44 \pm$
274 16% ; $P = 0.031$) than Period1 ($95 \pm 16\%$) for NRG treated horses ($P = 0.031$; Figure 3B). The
275 percent increase in muscle soreness and tightness was not affected by period for CON horses (P
276 > 0.9 ; Figure 3A).

277

278 **Discussion**

279 The primary objective of this experiment was to test the hypothesis that 30 d of dietary
280 supplementation with DigestaWell® NRG would reduce muscle soreness following a bout of
281 moderate-intensity exercise in horses that receive minimal ridden exercise. Secondly, we

282 hypothesized that horses receiving the supplement would have reduced concentrations of
283 circulating inflammatory cytokines and lactic acid following exercise. During this study, horses
284 carried 20% of their bodyweight. This weight was chosen as an intermediate between that of
285 25% previously shown to have an effect on heart rates and 17% previously shown to induce
286 lameness in riding horses [12, 13], as our goal was to utilize moderate exercise that induced
287 muscular soreness, but also to have horses complete the 50 minute exercise test without
288 becoming lame. The current study differs from that of Dyson et al., due to the use of lead
289 weights to adjust total weight instead of finding heavier riders, and this could account for
290 differences in post-exercise lameness. The exercise program increased heart rates and plasma
291 lactate concentrations to levels indicating that horses were being exercised at a moderate
292 intensity level [12, 31-33].

293 A principal finding of this study was that NRG supplemented horses experienced reduced
294 post exercise muscle soreness following the 30 d supplementation period. Yucca and fenugreek
295 possibly reduce muscle soreness through their protective effects on cell membrane lipids, which
296 when damaged during exercise [34], induce the sensing of pain through an increase in local
297 inflammation. Derivatives of yucca contain antioxidant activities that reduce cell membrane
298 peroxidation [35-38] while fenugreek inhibits the activity of the lipid peroxidase enzyme [22].
299 Fenugreek also downregulates pain sensing through inhibiting the activity of cyclooxygenase
300 (COX)-1, and COX-2, the enzymes that convert arachidonic acid to prostaglandins [22, 39].
301 Fenugreek has similar pain reduction levels to ibuprofen when administered to mice [15].
302 Although extracts of both yucca and fenugreek have been evaluated for their pain-relieving
303 activity, neither appears to have been previously tested in a model of exercise induced muscle
304 soreness despite widely accessible over-the-counter herbal supplements for humans and horses.

305 A relationship exists between post-exercise muscle soreness and inflammation in humans
306 [40]; with production of pro-inflammatory cytokines such as IL-1 β and TNF α increasing in
307 response to tissue damage [41]. These cytokines have a purpose of initiating clearance of
308 damaged tissue, peak 1-2 days post exercise, and are then down regulated by anti-inflammatory
309 cytokines following tissue cleanup [1, 42, 43]. Therefore, we were interested in evaluating the
310 inflammatory protein response to exercise. Unfortunately, our exercise protocol did not influence
311 IL-1 β or TNF α protein in either CON or NRG treated horses. These findings are inconsistent to
312 the findings of Liburt et al. [44], who reported increases in blood IL-1 β mRNA at 2 hours and
313 muscle and blood TNF α mRNA at 6 hours. However, many differences exist between the
314 methods of these two studies. The former research group measured mRNA expression in white
315 blood cells of blood and muscle, whereas we measured circulating protein concentrations. It is
316 now known that IL1 β is regulated at the level of protein secretion and a measurement of
317 increased mRNA expression without an increase in secreted protein, does not reflect the activity
318 of IL1 β protein [45]. We also captured a slightly shorter window at 4 h post exercise instead of 6.
319 The former study also included greater exercise intensity, type, and duration and it is most likely
320 that the horses on the Liburt et al. study experienced more soreness than horses used for the
321 present study. However, the purpose of this study was to investigate the potential benefits of
322 DigestaWell® NRG in moderately exercised horses, and therefore, the exercise protocol
323 employed in this study was of lower intensity.

324 An interesting finding of this study was the reduction in average TNF α concentrations in
325 NRG treated horses after 30 d of supplementation. One possible explanation for this finding is
326 that the extracts of *Yucca schidigera* and *Trigonella foenum-graecum* contain anti-inflammatory
327 activity. For instance, resveratrol is an extract of *yucca schidigera* that reduced TNF α protein

328 production in cultured equine lymphocytes [46]. This is similar to results in mouse models,
329 where resveratrol reduced TNF α protein in mouse spleen [47] and inhibits the TNF α response to
330 lipopolysaccharide stimulation in a mouse cell line [48, 49]. This is possibly through the effects
331 of yucca extracts to reduce LPS-induced binding of NF κ B to the promoter of target genes [37],
332 such as TNF α [50, 51]. Resveratrol also down regulates JAK1-STAT3 transcription factor
333 mRNA levels [47]. These two transcription factors are important for mediating the inflammatory
334 effects of TNF α in target cells [52]. Eight weeks of fenugreek seed powder supplementation also
335 reduced TNF α protein concentrations in human blood [53], which could be due to one or more of
336 the bioactive compounds contained in fenugreek: diosgenin, 4-OH-Ile, and galactomannan, all of
337 which purportedly contain anti-inflammatory activity.

338 Horses supplemented with DigestaWell NRG $\text{\textcircled{R}}$ had altered metabolic responses to the
339 moderate intensity exercise employed in this study. Unconditioned horses use a combination of
340 fats, blood glucose, and muscle glycogen as energy sources during low and moderate intensity
341 exercise (35% of VO $_{2\text{max}}$) [54], with muscle glycogen contributing 81% of energy at the start of
342 exercise and 44% by one hour into the test. Despite using multiple sources of energy,
343 unconditioned horses utilize aerobic metabolism until they reach speeds of about 4 m/s, at which
344 point plasma lactate concentrations begin to accumulate, indicating that unconditioned horses
345 increase their reliance on anaerobic mechanisms above this speed [55]. In that study, 11 weeks of
346 conditioning increased the breakpoint to nearly 6 m/s, suggesting that fitter horses could exercise
347 at the speeds used in our study without requiring anaerobic metabolism in contrast to
348 unconditioned horses. The capacity to utilize aerobic metabolism can be increased through
349 conditioning [56, 57], but it may also be possible to achieve increased aerobic capacity without
350 conditioning, as fenugreek-treated mice exhibited increased capacities for aerobic metabolism

351 [24]. In these mice, both muscle and liver glycogen contents were higher immediately post-
352 exercise than muscle and liver contents of untreated mice, supporting that fenugreek
353 supplementation could possibly alter metabolic responses to exercise. The tendency for lower
354 plasma lactate concentrations in NRG horses following exercise suggests that the dietary
355 supplement increased capacity for aerobic metabolism. Future research should investigate the
356 potential for reduced glycogen depletion following DigestaWell NRG® supplementation and in
357 horses undergoing a regular exercise program.

358 Limitations of this study include that we used only one licensed massage therapist to
359 perform muscle soreness and tightness scores. Unfortunately, we were unable to locate a second
360 licensed massage therapist within the geographical region. Similarly, Powell et al. [12] used one
361 licensed massage therapist to perform post-exercise muscles soreness and tightness scoring.
362 When visually evaluating behaviors indicating equine musculoskeletal pain, agreement among
363 trained veterinarians and behaviorists was 92% [8] and a second study evaluating lameness
364 found that agreement increased with experience level [58]. Physical therapists evaluating human
365 subjects' muscle tenderness to palpation reported an average of 72% agreement, with agreement
366 being highest (95%) for lumbar muscles [59]. The therapist utilized for this study had several
367 years of experience in the field and was blinded to treatments.

368 Future research using herbal supplements should include a flavonoid analysis. Flavonoids
369 are the active ingredients in herbs, therefore determining their presence and concentration
370 enables insights into the mechanism of a supplement's actions. Findings of this study can only be
371 related to the product in entirety and not to the components of the ingredients. Furthermore,
372 intakes of antioxidant-related minerals, such as selenium, zinc, and copper, and vitamins, such as
373 E and C, would potentially influence inflammatory responses post exercise. All horses met or

374 exceeded their estimated requirements for vitamin E, selenium, and copper, while zinc was
375 slightly low in pastured horses. However, all horses had *ad libitum* access to trace mineralized
376 salt blocks, and intake of micronutrients from salt blocks was not included in the calculations.
377 Therefore, it is highly likely that all horses met their copper and zinc requirements. Regretfully,
378 we were only able to obtain a vitamin C analysis on the NRG supplement, with findings that
379 vitamin C was undetectable and that the supplement provided NRG horses with an additional 3.7
380 IU of α -tocopherol per day. This is a small percentage of the average daily requirement of 500
381 IU (NRC, 2007), which was met by the other components of their diet, including fresh pasture, a
382 rich source of vitamin E [60]. While the stalled horses consumed several hours of pasture daily,
383 they also received a greater quantity of commercial concentrate, which was formulated to meet
384 vitamin E requirements when fed at rates between 0.5 and 0.7% of bodyweight (Southern States
385 Cooperative, Richmond, VA). Therefore, it is less likely that the observed differences were due
386 to the increased antioxidant intakes of NRG horses. In order to further address the effects of a
387 treatment on reducing inflammatory responses to exercise, plasma concentrations of TBARs and
388 PGE 2α could have been analyzed. Unfortunately, we lacked the funds necessary to complete
389 these analyses.

390 Finally, this study was conducted during the months of June and July, with similarly
391 warm and humid weather conditions during each of the SET's. June was slightly cooler (25.6°C,
392 73.8% humidity) than July (27.6°C, 77.6% humidity); however, both of these months exceeded
393 the thermoneutral zone of the horse, yielding a heat index of 152-159. This high heat index
394 would have required increased reliance on evaporative cooling mechanisms as compared to
395 exercise in cooler and drier conditions [61, 62]. Others have indicated the additional stress placed
396 on equine athletes to perform as the heat index increases above 150 [63, 64], with higher post

397 exercise plasma lactate concentrations and a more rapid time to fatigue in higher heat index
398 conditions. Notably, our horses did not experience higher lactate concentrations during Period2
399 (July), despite the higher heat index.

400 In conclusion, horses experienced altered metabolic responses to a moderate intensity
401 exercise trial following four weeks of DigestaWell® NRG supplementation. DigestaWell® NRG
402 supplementation may benefit exercising horses through reducing muscle soreness and tightness
403 as identified by massage and a tendency for reduced lactate production following exercise.
404 DigestaWell® NRG supplementation also reduced circulating TNF α concentrations.

405

406 **References**

- 407 [1] Peake JM, Neubauer O, Gatta PAD, Nosaka K. Muscle damage and inflammation during
408 recovery from exercise. *J Appl Physiol.* 2017;122:559-70.
- 409 [2] Fielding R, Manfredi T, Ding W, Fiatarone M, Evans W, Cannon JG. Acute phase response
410 in exercise. III. Neutrophil and IL-1 beta accumulation in skeletal muscle. *Am J Physiol Reg Int*
411 *Comp Physiol.* 1993;265:R166-R72.
- 412 [3] Cannon JG, Fielding RA, Fiatarone MA, Orencole SF, Dinarello CA, Evans WJ. Increased
413 interleukin 1 beta in human skeletal muscle after exercise. *Am J Physiol Reg Int Comp Physiol.*
414 1989;257:R451-R5.
- 415 [4] Hyldahl RD, Hubal MJ. Lengthening our perspective: Morphological, cellular, and molecular
416 responses to eccentric exercise. *Muscle & Nerve.* 2014;49:155-70.
- 417 [5] Yen Y-T, Tu P-H, Chen C-J, Lin Y-W, Hsieh S-T, Chen C-C. Role of acid-sensing ion
418 channel 3 in sub-acute-phase inflammation. *Molecular Pain.* 2009;5:1.
- 419 [6] Reeh PW, Kress M. Molecular physiology of proton transduction in nociceptors. *Curr*
420 *Opinion Pharmacol.* 2001;1:45-51.
- 421 [7] Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen
422 intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-
423 alpha, and lipopolysaccharide. *J Clin Invest.* 1995;95:1669-75.
- 424 [8] Dyson S, Berger J, Ellis AD, Mullard J. Development of an ethogram for a pain scoring
425 system in ridden horses and its application to determine the presence of musculoskeletal pain. *J*
426 *Vet Behav Clin Appl Res.* 2018;23:47-57.
- 427 [9] Barstow A, Dyson S. Clinical features and diagnosis of sacroiliac joint region pain in 296
428 horses: 2004–2014. *Equine Vet Ed.* 2015;27:637-47.
- 429 [10] Ross MW, Dyson SJ. *Diagnosis and Management of Lameness in the Horse-E-Book:*
430 Elsevier Health Sciences; 2010.

- 431 [11] Dittmann MT, Latif SN, Hefti R, Hartnack S, Hungerbühler V, Weishaupt MA. Husbandry,
432 use, and orthopaedic health of horses owned by competitive and leisure riders in Switzerland. J
433 Equine Vet Sci. 2020;103107.
- 434 [12] Powell DM, Bennett-Wimbush K, Peeples A, Duthie M. Evaluation of indicators of weight-
435 carrying ability of light riding horses. J Equine Vet Sci. 2008;28:28-33.
- 436 [13] Dyson S, Ellis AD, Mackechnie-Guire R, Douglas J, Bondi A, Harris P. The influence of
437 rider:horse bodyweight ratio and rider-horse-saddle fit on equine gait and behaviour: A pilot
438 study. Equine Vet Ed. 2019;32:527-39.
- 439 [14] NAHMS. Equine 2015. Changes in the U.S. Equine Industry, 1998–2015. Fort Collins, CO:
440 US Department of Agriculture; 2017.
- 441 [15] Mandegary A, Pournamdari M, Sharififar F, Pournourmohammadi S, Fardiar R, Shooli S.
442 Alkaloid and flavonoid rich fractions of fenugreek seeds (*Trigonella foenum-graecum* L.) with
443 antinociceptive and anti-inflammatory effects. Food Chem Toxicol. 2012;50:2503-7.
- 444 [16] Williamson EM, Liu X, Izzo AA. Trends in use, pharmacology, and clinical applications of
445 emerging herbal nutraceuticals. Br J Pharmacol. 2020;177:1227-40.
- 446 [17] Oke SL, McIlwraith CW. Review of the economic impact of osteoarthritis and oral joint-
447 health supplements in horses. AAEP Proceedings. Baltimore, MD. 2010. p. 12-8.
- 448 [18] Burk AO, Williams CA. Feeding management practices and supplement use in top-level
449 event horses. Comp Ex Physiol. 2008;5:85-93.
- 450 [19] Hoffman CJ, Costa LR, Freeman LM. Survey of Feeding Practices, Supplement Use,
451 and Knowledge of Equine Nutrition among a Subpopulation of Horse Owners in New England. J
452 Equine Vet Sci. 2009;29:719-26.
- 453 [20] Cheeke PR, Piacente S, Oleszek W. Anti-inflammatory and anti-arthritic effects of yucca
454 schidigera: A review. J Inflamm. 2006;3:6.
- 455 [21] Alarcón de la Lastra C, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent:
456 Mechanisms and clinical implications. Mol Nutr Food Res. 2005;49:405-30.
- 457 [22] Liu Y, Kakani R, Nair MG. Compounds in functional food fenugreek spice exhibit anti-
458 inflammatory and antioxidant activities. Food Chem. 2012;131:1187-92.
- 459 [23] Kumar GP, Anand T, Singsit D, Khanum F, Anilakumar KR. Evaluation of antioxidant and
460 anti-fatigue properties of *Trigonella foenum-graecum* L. in rats subjected to weight loaded
461 forced swim test. Pharmacognosy J. 2013;5:66-71.
- 462 [24] Ikeuchi M, Yamaguchi K, Koyama T, Sono Y, Yazawa K. Effects of fenugreek seeds
463 (*Trigonella foenum graecum*) extract on endurance capacity in mice. J Nutr Science
464 Vitaminology. 2006;52:287-92.
- 465 [25] Ruby BC, Gaskill SE, Slivka D, Harger SG. The addition of fenugreek extract (*Trigonella*
466 *foenum-graecum*) to glucose feeding increases muscle glycogen resynthesis after exercise.
467 Amino Acids. 2005;28:71-6.
- 468 [26] Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score,
469 physical measurements and body fat percentage in mares. Equine Vet J. 1983;15:371-2.
- 470 [27] Dowler LE, Siciliano PD, Pratt-Phillips SE, Poore M. Determination of pasture dry matter
471 intake rates in different seasons and their application in grazing management. J Equine Vet Sci.
472 2012;32:85-92.
- 473 [28] LaCasha PA, Brady HA, Allen VG, Richardson CR, Pond KR. Voluntary intake,
474 digestibility, and subsequent selection of *Matua* bromegrass, coastal bermudagrass, and alfalfa
475 hays by yearling horses. J Anim Sci. 1999;77:2766-73.

476 [29] Suagee JK, Burk AO, Quinn RW, Hartsock TG, Douglass LW. Effects of diet and weight
477 gain on circulating tumour necrosis factor- α concentrations in Thoroughbred geldings. *J Anim*
478 *Physiol Anim Nutr.* 2011;95:161-70.

479 [30] Suagee-Bedore JK, Wagner AL, Girard ID. Validation of the postprandial interleukin-1 β
480 response in horses using equine-specific antibodies. *J Equine Vet Sci.* 2017;48:69-72.

481 [31] NRC. *Nutrient Requirements of Horses.* 6th rev ed. Washington, DC: National Academies
482 Press; 2007.

483 [32] Prince A, Geor R, Harris P, Hoekstra K, Gardner S, Hudson C, et al. Comparison of the
484 metabolic responses of trained Arabians and Thoroughbreds during high- and low-intensity
485 exercise. *Equine Vet J.* 2002;34:95-9.

486 [33] Eaton MD, Hodgson DR, Evans DL, Rose RJ. Effects of low- and moderate-intensity
487 training on metabolic responses to exercise in Thoroughbreds. *Equine Vet J.* 1999;31:521-7.

488 [34] Mills P, Ng J, Thornton J, Seawright A, Auer D. Exercise-induced connective tissue
489 turnover and lipid peroxidation in horses. *Br Vet J.* 1994;150:53-63.

490 [35] Oleszek W, Sitek M, Stochmal A, Piacente S, Pizza C, Cheeke P. Resveratrol and Other
491 Phenolics from the Bark of *Yucca schidigera* Roezl. *J Ag Food Chem.* 2001;49:747-52.

492 [36] Piacente S, Pizza C, Oleszek W. Saponins and Phenolics of *Yucca schidigera* Roezl:
493 Chemistry and Bioactivity. *Phytochemistry Rev.* 2005;4:177-90.

494 [37] Marzocco S, Piacente S, Pizza C, Oleszek W, Stochmal A, Pinto A, et al. Inhibition of
495 inducible nitric oxide synthase expression by yuccaol C from *Yucca schidigera* roezl. *Life*
496 *Sciences.* 2004;75:1491-501.

497 [38] Kucukkurt I, Ince S, Fidan AF, Ozdemir A. The effects of dietary supplementation of
498 different amount of *Yucca schidigera* powder (Sarsaponin 30®) on blood and tissue antioxidant
499 defense systems and lipid peroxidation in rats. *J Anim Vet Adv.* 2008;7:1413-7.

500 [39] Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and
501 revealing therapeutic targets. *Trends Mol Med.* 2002;8:390-6.

502 [40] Farias-Junior LF, Browne RAV, Freire YA, Oliveira-Dantas FF, Lemos TMAM, Galvão-
503 Coelho NL, et al. Psychological responses, muscle damage, inflammation, and delayed onset
504 muscle soreness to high-intensity interval and moderate-intensity continuous exercise in
505 overweight men. *Physiol Behav.* 2019;199:200-9.

506 [41] Liao P, Zhou J, Ji LL, Zhang Y. Eccentric contraction induces inflammatory responses in rat
507 skeletal muscle: role of tumor necrosis factor- α . *Am J Physiol Reg Int Comp Physiol.*
508 2010;298:R599-R607.

509 [42] Suzuki K. Cytokine response to exercise and its modulation. *Antioxidants.* 2018;7:17.

510 [43] Gomez-Cabrera MC, Viña J, Ji LL. Role of redox signaling and inflammation in skeletal
511 muscle adaptations to training. *Antioxidants.* 2016;5:48.

512 [44] Liburt NR, Adams AA, Betancourt A, Horohov DW, McKeever KH. Exercise-induced
513 increases in inflammatory cytokines in muscle and blood of horses. *Equine Vet J Suppl.*
514 2010:280-8.

515 [45] Schroder K, Tschopp J. The Inflammasomes. *Cell.* 2010;140:821-32.

516 [46] Siard MH, McMurry KE, Adams AA. Effects of polyphenols including curcuminoids,
517 resveratrol, quercetin, pterostilbene, and hydroxypterostilbene on lymphocyte pro-inflammatory
518 cytokine production of senior horses in vitro. *Vet Immunol Immunopath.* 2016;173:50-9.

519 [47] Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alzahrani MZ, Alshammari MA, et al.
520 Resveratrol attenuates pro-inflammatory cytokines and activation of JAK1-STAT3 in BTBR T+
521 Itr3tf/J autistic mice. *Europ J Pharmacol.* 2018;829:70-8.

522 [48] Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, et al. Resveratrol inhibits nitric
523 oxide and TNF- α production by lipopolysaccharide-activated microglia. *International*
524 *Immunopharmacology*. 2005;5:185-93.

525 [49] Palacz-Wrobel M, Borkowska P, Paul-Samojedny M, Kowalczyk M, Fila-Danilow A,
526 Suchanek-Raif R, et al. Effect of apigenin, kaempferol and resveratrol on the gene expression
527 and protein secretion of tumor necrosis factor alpha (TNF- α) and interleukin-10 (IL-10) in
528 RAW-264.7 macrophages. *Biomedicine & Pharmacotherapy*. 2017;93:1205-12.

529 [50] Crinelli R, Antonelli A, Bianchi M, Gentilini L, Scaramucci S, Magnani M. Selective
530 Inhibition of NF- κ B Activation and TNF- α Production in Macrophages by Red Blood Cell-
531 Mediated Delivery of Dexamethasone. *Blood Cells, Molecules, and Diseases*. 2000;26:211-22.

532 [51] Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by
533 NF- κ B. *Trends Cell Biol*. 1998;8:107-11.

534 [52] Miscia S, Grilli A, Valerio V, Centurione L, Sabatino G, Garaci F, et al. Tumor necrosis
535 factor α (TNF- α) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. *Cell*
536 *Growth Different*. 2002;13:13-8.

537 [53] Tavakoly R, Maracy MR, Karimifar M, Entezari MH. Does fenugreek (*Trigonella foenum-*
538 *graecum*) seed improve inflammation, and oxidative stress in patients with type 2 diabetes
539 mellitus? A parallel group randomized clinical trial. *Europ J Integr Med*. 2018;18:13-7.

540 [54] Pagan JD, Geor RJ, Harris PA, Hoekstra K, Gardner S, Hudson C, et al. Effects of fat
541 adaptation on glucose kinetics and substrate oxidation during low-intensity exercise. *Equine Vet*
542 *J Suppl*. 2002:33-8.

543 [55] Kronfeld DS, Custalow SE, Ferrante PL, Taylor LE, Moll HD, Meacham TN, et al.
544 Determination of the lactate breakpoint during incremental exercise in horses adapted to dietary
545 corn oil. *Am J Vet Res*. 2000;61:144-51.

546 [56] Cutmore C, Snow D, Newsholme E. Activities of key enzymes of aerobic and anaerobic
547 metabolism in middle gluteal muscle from trained and untrained horses. *Equine Vet J*.
548 1985;17:354-6.

549 [57] Piccione G, Messina V, Casella S, Giannetto C, Caola G. Blood lactate levels during
550 exercise in athletic horses. *Comp Clin Path*. 2010;19:535-9.

551 [58] Hammarberg M, Egenvall A, Pfau T, Rhodin M. Rater agreement of visual lameness
552 assessment in horses during lungeing. *Equine Vet J*. 2016;48:78-82.

553 [59] Eriksson EM, Mokhtari M, Pourmotamed L, Holmdahl L, Eriksson H. Inter-rater reliability
554 in a resource-oriented physiotherapeutic examination. *Physiotherap Theory Prac*. 2000;16:95-
555 103.

556 [60] Fagan MM, Harris P, Adams A, Pazdro R, Krotky A, Call J, et al. Form of vitamin E
557 supplementation affects oxidative and inflammatory response in exercising horses. *J Equine Vet*
558 *Sci*. 2020;91:103103.

559 [61] Hodgson DR, Davis RE, McConaghy FF. Thermoregulation in the horse in response to
560 exercise. *Br Vet J*. 1994;150:219-35.

561 [62] Mackay-Smith M, Cohen M. Exercise physiology and diseases of exertion. *Equine Med*
562 *Surg*. 1982;3:117-29.

563 [63] Febbraio MA, Snow RJ, Stathis CG, Hargreaves M, Carey MF. Effect of heat stress on
564 muscle energy metabolism during exercise. *J Appl Physiol*. 1994;77:2827-31.

565 [64] Marlin DJ, Scott CM, Schroter RC, Mills PC, Harris RC, Harris PA, et al. Physiological
566 responses in nonheat acclimated horses performing treadmill exercise in cool (20 degrees C/40%

567 RH), hot dry (30 degrees C/40% RH) and hot humid (30 degrees C/80% RH) conditions. Equine
568 Vet J Suppl. 1996;22:70-84.

569

570 **Tables**

571 **Table 1.**

Table 1. Number of horses within each age block that were assigned to the control (CON) or treatment (NRG).

Treatment	11-15 years	16-20 years	>20 years
NRG	6	2	2
CON	5	3	2

572

573

574

Table 2. Bodyweight and body condition scores of horses prior to (Period 1) and after (Period 2) a 4-week supplementation period with 200 g DigestaWell® NRG per day.

	CON	NRG	SEM	<i>P</i> Values		
	<i>Bodyweight, kg</i>			Treatment	Period	Treatment x Period
Period 1	547	574	20	0.26	0.65	0.11
Period 2	543	581				
	<i>Body Condition Score</i>					
Period 1	6.0	5.5	0.3	0.28	0.27	0.71
Period 2	6.2	5.8				

575

576

577

Table 3. Dry matter nutritional content of forages and concentrates provided to horses prior to and during the 4-week supplementation period with 200 g DigestaWell® NRG per day.

Nutrient	Hay	Pasture	Feed1 ^a	Feed2 ^b	Supplement ^c
DE, Mcal/kg	1.81	2.29	3.04	3.28	3.34
CP, %	9.6	22.4	22.4	14.6	13.0
ADF, %	42.6	27.9	19.3	11.3	18.0
NDF, %	68.1	50.3	30.8	25.3	21.6
ESC, %	2.5	8.6	6.1	5.1	3.7
WSC, %	6.8	12.2	6.0	12.0	3.7
Starch, %	0.4	1.0	18.4	24.6	3.3
NSC,%	2.9	9.6	24.7	29.7	7.0
Fat, %	2.6	4.5	5.78	10.0	7.0
Vitamin C, ppm	NA	NA	NA	NA	<4
α-tocopherol acetate IU/g	61	162	150	100	0.02
Zinc	30	26	100	166	6
Copper	7	9	9	47	0.6
Selenium	0.06	0.16	0.35	0.6	-
Yucca, mg/g	-	-	-	-	8.7
Fenugreek, mg/g	-	-	-	-	36.0

^aFeed provided to horses housed on pasture (n=16), horses provided with 0.2 kg per day.

^bFeed provided to horses housed in stalls (n=3), horses provided with 2.3 kg per day.

^cNutrients contained in composited supplement.

NA= not available.

578

579

Table 4. Average (\pm SD) daily nutrient intakes in control horses (CON) and horses supplemented with 200 g DigestaWell® NRG (NRG) per day for 4 weeks.

Nutrient	CON		NRG	
	Stall (n=1)	Pasture (n=9)	Stall (n=2)	Pasture (n=7)
DE, Mcal	31.2	23.9 \pm 2.3	35.9 \pm 1.3	26.2 \pm 4.0
CP, g	1934	2350 \pm 228	1959 \pm 74	2533 \pm 392
ESC, g	547	902 \pm 88	588 \pm 22	969 \pm 150
WSC, g	1095	1280 \pm 124	1374 \pm 52	1370 \pm 213
Starch, g	480	105 \pm 10	628 \pm 24	134 \pm 18
NSC, g	1576	1385 \pm 134	2001 \pm 76	1504 \pm 231
Fat, g	496	472 \pm 46	693 \pm 26	518 \pm 79
α -tocopherol acetate, IU	1682	1710 \pm 166	1803 \pm 269	1633 \pm 62
Zinc, mg	614	280 \pm 27	902 \pm 34	303 \pm 46
Copper, mg	114	95 \pm 9	102 \pm 16	238 \pm 9
Selenium, mg	2.3	1.7 \pm 0.2	2.7 \pm 0.1	2.0 \pm 0.4

580

581

Table 5. Characteristics of the standardized exercise test and average heart rates (beats per minute \pm SEM) of horses prior to (Period 1) and after (Period 2) a 4-week supplementation period with 200 g DigestaWell® NRG per day (NRG) and unsupplemented controls (CON).

Gait	Pace, m/s	Time, min	Heart Rate, beats per min, CON			Heart rate, beats per min, NRG		
			Period 1 \pm 3.0	Period 2 \pm 3.2	AVE \pm 2.2	Period 1 \pm 3.5	Period 2 \pm 3.5	AVE \pm 2.5
Baseline	---	---	44	42	43	36	39	37
PreEx	---	---	53	50	51 ^{***}	50	47	49 [*]
Walk	Brisk	2.5	70	67	69 ^{***}	72	66	69 ^{***}
Trot	3	15	105	106	106 ^{***}	110	107	109 ^{***}
Canter	5	5	132	130	131 ^{***}	137	136	136 ^{***}
Trot	3	2.5	112	112	112 ^{***}	118	114	116 ^{***}
Reverse	---	---	---	---	---	---	---	---
Walk	Brisk		87	87	90 ^{***}	90	89	90 ^{***}
Trot	3	2.5	113	114	113 ^{***}	118	118	118 ^{***}
Canter	5	15	128	134	131 ^{***}	139	137	138 ^{***}
Trot	3	5	116	116	116 ^{***}	123	124	123 ^{***}
Post-10		2.5	60	58	59 ^{***}	54	59	57 ^{***}
Post-30			53	49	51	39	48	43
Total		50						

*Within rows $P < 0.05$ for values compared to baseline.

***Within rows $P < 0.001$ for values compared to baseline.

582

583

Table 6. The percent increase in muscle soreness and tightness following a 50 minute standardized exercise test in which control (CON) horses and horses supplemented daily with DigestaWell® NRG (NRG) carried 20% of their body weight.^a

Treatment	Period1 ^b	Period2 ^c	<i>P</i> -value
CON	59.1 ± 11.1	58.1 ± 11.4	0.9
NRG	94.9 ± 16.3	43.8 ± 16.3	0.031


^aPercent increase calculated as (post-exercise muscle soreness – pre-exercise muscle soreness)/pre-exercise muscle soreness.

^bPeriod1 reflects values obtained prior to the study period.

^cPeriod2 values were obtained after 4 wk.

586 **Figures**

587 **Fig. 1**




588

589 **Figure 1.** Timeline of data and sample collection from horses completing a standardized exercise
590 test, where arrows with diagonal stripes indicate blood sampling time points, black arrows
591 indicate when heart rate was obtained, and arrows with dots indicate massage testing for muscle
592 soreness and tightness. Speeds during exercise test are approximate. Heart rates during exercise
593 test were obtained at the end of the speed, prior to switching gaits.

594

595 **Fig 2.**




596

597


598

599 **Figure 2.** Plasma glucose (A, B), lactate (C, D), and non-esterified fatty acids (NEFA; E, F)
600 concentrations prior to (PreEx) and following a 50 min standardized exercise test. Samples were
601 collected from unsupplemented controls (A, C, E) and horses supplemented daily with
602 DigestaWell® NRG (B, D, F) prior to the study (Period 1, black bars) and after 4 wk (Period 2,
603 white bars). ^{ab}Means with unlike superscripts differ from PreEx $P < 0.05$.

604 **Fig. 3**



605



606

607

608 **Figure 3.** Mean and 95% confidence interval plasma tumor necrosis factor- α (TNF α)
609 concentrations during a 50 min standardized exercise test. Samples were collected from
610 unsupplemented controls (A) and horses supplemented daily with DigestaWell ® NRG (B) prior
611 to the study (Period 1) and after 4 wk (Period 2).

612